Drug Prices, Foreign Exchange Volatility and New Tax Rules: A 2026 compliance strategy guide for Nigeria’s pharmaceutical sector

Nigeria’s macroeconomic outlook for 2026 presents cautious optimism. Headline inflation moderated to 15.10% in January 2026, with the National Bureau of Statistics subsequently reporting 15.06% in February 2026, indicating a modest easing in general price growth, and the operating environment appears to reflect relatively greater exchange-rate stability when compared with the sharp volatility experienced in the immediate aftermath of earlier FX liberalisation measures.

However, for pharmaceutical companies, these improvements have not translated into immediate pricing relief or margin stability. Healthcare inflation, which accelerated to 30.35% in early 2026 due to the lagged effects of earlier currency shocks continues to outpace general inflation and remains a critical driver of drug affordability and market access challenges.

For pharmaceutical manufacturers and importers, the issue is no longer limited to rising costs. It now extends to how FX exposure, drug pricing pressure, regulatory scrutiny, and the new tax framework introduced in January 2026 interact to shape profitability and compliance risk. The key question for boards and senior management is how to operate sustainably within this new environment while remaining competitive, compliant, and commercially viable.

Drug Prices and Structural Pressures

Recent releases from the National Bureau of Statistics (NBS) show that while headline inflation has eased, healthcare inflation remains persistently elevated. This shows structural cost pressures within the pharmaceutical value chain rather than temporary macroeconomic shocks. These pressures directly affect how drugs are priced, distributed, and accessed across the Nigerian market.

The heavy reliance on imported active pharmaceutical ingredients (APIs), high energy and logistics costs, limited local manufacturing capacity, and elevated financing costs continue to constrain pricing flexibility. In practical terms, these factors limit manufacturers’ ability to absorb costs without passing them on to distributors or patients. In addition, market exits, supply rationalisation, and restructuring by some multinational and large market participants have contributed to supply-side pressure in parts of the sector. A consequential risk is the growing shift toward informal medicine channels, which raises serious public health and regulatory concerns.

Foreign Exchange Volatility and Its Impact on Pharmaceutical Operations

Nigeria’s pharmaceutical industry remains structurally import-dependent, making Foreign Exchange (FX) volatility a direct determinant of drug pricing, procurement planning, and working capital management. Even locally packaged products rely heavily on imported raw materials, meaning currency movements immediately affect landed costs and inventory valuation.

A critical tax-compliance implication under the Nigeria Tax Act (NTA) 2025 is that expenses incurred in foreign currency are deductible only at the official Nigerian Naira (NGN) exchange rate. This means that where a business sources foreign exchange at a premium above the official rate, the excess may not be recognised for tax deduction purposes. A marginal depreciation of the Naira can immediately alter landed costs, and companies must account for the fact that any premium paid in the unofficial market is not tax-deductible. Dollar scarcity compounds the risk, forcing companies to reprice inventory or delay procurement.

While the Federal Government’s target of achieving 70% local drug manufacturing by 2030 is commendable achieving this will require sustained FX stability, access to concessionary financing, and infrastructure support to translate policy ambition into commercial reality.

The 2026 Tax Reforms: A New Compliance Landscape

The Nigeria Tax Act (NTA) 2025, which became effective on January 1, 2026, consolidated and repealed several prior tax statutes. These reforms reshape the fiscal environment for the pharmaceutical sector.

1. Recovery of Input Value Added Tax (VAT)

The Nigeria Tax Act (NTA) 2025 introduces reforms that materially affect the cost structure of pharmaceutical operations. The expanded recovery of input Value Added Tax (VAT) under Section 156(5) now allows manufacturers to offset VAT incurred on services and fixed assets, improving cash flow and reducing the embedded tax cost of production. For pharmaceutical companies with capital-intensive operations, this reform directly enhances pricing flexibility and project viability. This benefit, however, will depend on proper invoicing, documentation, and the company’s ability to substantiate recoverable input VAT under the new regime.

2. Expansion of Zero-Rated Value Added Tax (VAT)

Similarly, the reclassification of certain essential medical and pharmaceutical products from VAT-exempt to zero-rated under Section 187 preserves the right to full input VAT recovery. This eliminates the hidden “tax-on-tax” effect that previously inflated production costs and placed locally manufactured drugs at a competitive disadvantage. When properly utilised, this reform can support more competitive pricing and improve the commercial attractiveness of local manufacturing.

3. Economic Development Tax Credit

The transition toward an investment-linked credit system materially improves the long-term project viability of local pharmaceutical manufacturing by rewarding sustained capital injection. By linking relief to actual investment rather than time-bound holidays, this performance-based model encourages the modernization of factory facilities and production lines. Pursuant to Sections 166 and 177 of the Nigeria Tax Act (NTA) 2025, the Economic Development Incentive (EDI) framework provides an annual tax credit of 5% on qualifying capital expenditure. Under Sections 178 and 181, this credit is claimable for an initial five-year period, with the added benefit of a five-year carry-forward for any unutilized portions.

4. Research and Development (R&D) Deduction Reform

Recalibrating innovation incentives to a turnover-based model provides a critical fiscal cushion for companies in the capital-intensive stages of drug development. This shift ensures that Research and Development (R&D) investments yield immediate tax benefits even during periods of margin compression, effectively anchoring innovation policy into the revenue base. Under Section 165 of the Nigeria Tax Act (NTA) 2025, the previous deduction of 10% of total profits has been replaced with a more inclusive cap of 5% of annual turnover, ensuring that firms with significant innovation costs but slim margins can fully leverage these incentives.

5. Introduction of a 15% Minimum Effective Tax Rate (METR)

The implementation of a statutory tax liability threshold requires large-scale pharmaceutical manufacturers to balance the utilization of incentives with a mandatory baseline contribution. For organizations with high turnover or global footprints, this provision necessitates a more sophisticated approach to tax planning to ensure that utilized credits do not inadvertently trigger additional top-up tax liabilities. Pursuant to Section 57 of the Nigeria Tax Act (NTA) 2025, a Minimum Effective Tax Rate (METR) of 15% now applies to companies with an aggregate annual turnover of ₦20 billion or more, as well as constituent entities of Multinational Enterprise (MNE) groups. Consequently, companies must carefully monitor their Effective Tax Rate (ETR).

A 2026 Compliance Strategy for Pharmaceutical Companies

In 2026, compliance is no longer a back-office function for pharmaceutical companies. It has become a strategic, board-level issue that directly affects pricing integrity, tax efficiency, regulatory credibility, and access to government incentives.

1. Proactive Tax Governance: Pharmaceutical companies must move beyond manual processing toward digital tax systems capable of real-time Value Added Tax (VAT) reconciliation. Under the Nigeria Tax Administration Act (NTAA) 2025, the Nigeria Revenue Service (NRS) has mandated the Electronic Fiscal System (EFS) for real-time invoice validation. This is essential for defending input Value Added Tax (VAT) claims on services and fixed assets, which are now recoverable under Section 156 of the Nigeria Tax Act (NTA) 2025.

 

2. Strategic Regulatory Alignment: Engagement with the National Agency for Food and Drug Administration and Control (NAFDAC) must be strategic. Companies should leverage the NAFDAC Reliance Guidelines 2025, which allow for the accelerated registration of products already approved by stringent global authorities [such as the World Health Organization (WHO) or the United States Food and Drug Administration (FDA)]. This pathway reduces redundant local evaluations and accelerates market access.

 

3. Institutionalizing a Culture of Governance: A robust governance framework is now a statutory prerequisite for accessing the Economic Development Incentive (EDI). The Nigeria Tax Act (NTA) 2025 has transitioned from unconditional tax exemptions toward performance-based tax credits tied to Qualifying Capital Expenditure (QCE). Transparent reporting is vital to secure these 5% credits and facilitate access to institutional financing.

 

3. Foreign Exchange (FX) and Cost Efficiency Modelling: Companies must integrate FX risk analysis into their pricing models. Under Section 20(4) of the Nigeria Tax Act (NTA) 2025, foreign currency expenses are deductible only at the official Central Bank of Nigeria (CBN) exchange rate. Boards must ensure procurement is aligned with these rates to avoid non-deductible tax leakages.

Conclusion

The Nigerian pharmaceutical sector now sits at the intersection of pricing pressure, FX exposure, and a fundamentally restructured tax regime. While macroeconomic indicators suggest gradual stabilisation, sustainable growth will depend on how effectively companies integrate tax efficiency, FX discipline, and regulatory compliance into their pricing and market access strategies. Pharmaceutical companies that treat compliance as a commercial advantage will be better positioned to stabilise prices, protect margins, and attract long-term investment in Nigeria’s evolving healthcare industry.

In practical terms, the companies most likely to outperform in this environment will be those that treat pricing, tax, regulatory strategy, and foreign-exchange management as interconnected governance issues rather than isolated operational problems.

Francisca Igboanugo is a Team Lead in the Health & Pharmaceutical Sector at Stren & Blan Partners, while Omolola Ambrose is a Senior Associate and Oluchukwu Nwakor and Eniola Alayo are Associates in the same sector.

 

Stren & Blan Partners is a full-service commercial Law Firm that provides legal services to diverse local and international Clientele. The Business Counsel is a weekly column by Stren & Blan Partners that provides thought leadership insight on business and legal matters.

Connect with Stren & Blan Partners:

Website: www.strenandblan.com

LinkedIn: linkedin.com/company/strenandblan

Twitter: twitter.com/Strenandblan

Instagram: instagram.com/strenandblan